Biotech · Private company
SystImmune Inc.
Track this companyFree. Adds SystImmune Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials108 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- BL-M14D1 and AtezolizumabPhase 3 · Small Cell Lung Cancer Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and LurbinectedinPhase 3 · Small Cell Lung Cancer Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)Phase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- T-Bren, Dose level 1Phase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- T-bren, Dose level 2Phase 3 · Urothelial CancerClinicalTrials.gov · fetched Nov 12, 2026
- BL-B01D1Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- BL-M05D1Phase 1 · Gastric AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- BL-M07D1Phase 1 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- BL-M11D1Phase 1 · Relapsed/Refractory Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BL-M14D1Phase 1 · Small Cell Lung Cancer Metastatic or Locally AdvancedClinicalTrials.gov · fetched Nov 12, 2026
- BL-M17D1Phase 1 · Breast Cancer Stage IIIClinicalTrials.gov · fetched Nov 12, 2026
- SI-B036Phase 1 · Locally Advanced /Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyPHASE3 · RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07869836 · fetched Nov 12, 2026
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)PHASE3 · RECRUITING · started Aug 4, 2026ClinicalTrials.gov NCT07625644 · fetched Nov 12, 2026
- SI-B036-ST-101 in Advanced/Metastatic Solid TumorsPHASE1 · RECRUITING · started Jul 30, 2026ClinicalTrials.gov NCT07857616 · fetched Nov 12, 2026
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)PHASE2_PHASE3 · RECRUITING · started Sep 11, 2025ClinicalTrials.gov NCT06926868 · fetched Nov 12, 2026
- Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 30, 2025ClinicalTrials.gov NCT07021066 · fetched Nov 12, 2026
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsPHASE1 · RECRUITING · started Apr 28, 2025ClinicalTrials.gov NCT07080242 · fetched Nov 12, 2026
- Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsPHASE1 · TERMINATED · started Apr 10, 2025ClinicalTrials.gov NCT06714617 · fetched Nov 12, 2026
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1PHASE1 · TERMINATED · started Dec 19, 2024ClinicalTrials.gov NCT06714591 · fetched Nov 12, 2026
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsPHASE1 · RECRUITING · started Feb 9, 2024ClinicalTrials.gov NCT06293898 · fetched Nov 12, 2026
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsPHASE1 · RECRUITING · started Aug 8, 2023ClinicalTrials.gov NCT05983432 · fetched Nov 12, 2026